Plain-English translation of NCT05040555 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing a four-drug chemotherapy combination called R-CDOP for people newly diagnosed with aggressive forms of non-Hodgkin's lymphoma who have significant tumor burden (meaning large or widespread tumors). The treatment includes rituximab, cyclophosphamide, doxorubicin hydrochloride liposome, vindesine, and prednisone given together in cycles. Researchers want to see how well this medication works and whether it is safe for patients like you.
People with aggressive lymphoma that has spread or formed large tumors often need stronger treatment options. This trial exists to test whether this new drug combination can better control the disease while being tolerable for patients with high tumor burden.
You likely qualify if…
You likely don't qualify if…
You would receive the four-drug chemotherapy combination through planned visits, with rituximab given on day 0 and the other three drugs plus prednisone given on days 1–5 of each treatment cycle. You would need regular blood tests, imaging scans, and heart function checks to monitor how well the treatment is working and watch for side effects. The study involves 64 participants total, and you would be monitored closely throughout your treatment and follow-up visits as outlined in the research schedule.
AI-generated summary from trial data · Aug 5, 2026 · Not medical advice
China